NasdaqGS:ZVRAPharmaceuticals
Profit Swing, MIPLYFFA Uptake and New CFO Might Change The Case For Investing In Zevra Therapeutics (ZVRA)
Zevra Therapeutics, Inc. has reported its 2025 results, with full-year sales rising to US$106.47 million and net income reaching US$83.23 million, alongside fourth-quarter revenue of US$34.1 million and adjusted earnings of US$1.16 per share.
Alongside these results, Zevra filed a US$22.86 million employee stock offering and named veteran finance executive Justin Renz as its new Chief Financial Officer, underscoring a focus on commercial scale-up and corporate development.
We’ll now examine...